WINDTREE THERAPEUTICS INC (WINT) Stock Price, Quote, News and Overview
NASDAQ:WINT - Nasdaq - US97382D6004 - Common Stock - Currency: USD
WINT Quote, Performance and Key Statistics
0.82
+0.03 (+3.81%)
The current stock price of WINT is 0.82 USD. In the past month the price decreased by -24.77%. In the past year, price decreased by -99.58%.
WINT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 327.00B | ||
| AMGN | AMGEN INC | 13.25 | 147.86B | ||
| GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
| ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
| NTRA | NATERA INC | N/A | 21.01B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
Related stock screener links
About WINT
Company Profile
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 14 full-time employees. The firm is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Its lead product candidate, istaroxime, is a dual-acting agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure (AHF) and reverse the hypotension and hypoperfusion associated with heart failure that deteriorates to cardiogenic shock. The firm also has a licensing business model with partnership out-licenses in place.
Company Info
WINDTREE THERAPEUTICS INC
2600 Kelly Rd Ste 100
Warrington PENNSYLVANIA 18976 US
CEO: Craig E. Fraser
Employees: 14
Phone: 12154889300
WINDTREE THERAPEUTICS INC / WINT FAQ
What is the stock price of WINDTREE THERAPEUTICS INC today?
The current stock price of WINT is 0.82 USD. The price increased by 3.81% in the last trading session.
What is the ticker symbol for WINDTREE THERAPEUTICS INC stock?
The exchange symbol of WINDTREE THERAPEUTICS INC is WINT and it is listed on the Nasdaq exchange.
On which exchange is WINT stock listed?
WINT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for WINDTREE THERAPEUTICS INC stock?
6 analysts have analysed WINT and the average price target is 180.54 USD. This implies a price increase of 21917.07% is expected in the next year compared to the current price of 0.82. Check the WINDTREE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is WINDTREE THERAPEUTICS INC worth?
WINDTREE THERAPEUTICS INC (WINT) has a market capitalization of 2.99M USD. This makes WINT a Nano Cap stock.
How many employees does WINDTREE THERAPEUTICS INC have?
WINDTREE THERAPEUTICS INC (WINT) currently has 14 employees.
What are the support and resistance levels for WINDTREE THERAPEUTICS INC (WINT) stock?
WINDTREE THERAPEUTICS INC (WINT) has a resistance level at 0.91. Check the full technical report for a detailed analysis of WINT support and resistance levels.
Should I buy WINDTREE THERAPEUTICS INC (WINT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of WINT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of WINT, evaluating the profitability, health, valuation and growth aspects
- WINDTREE THERAPEUTICS INC (WINT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- WINDTREE THERAPEUTICS INC (WINT) Sales and EPS estimates to see what analysts future expectations are.
- WINDTREE THERAPEUTICS INC (WINT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- WINDTREE THERAPEUTICS INC (WINT) Insider and Institutional Ownership to learn about the owners and their transactions.
- WINDTREE THERAPEUTICS INC (WINT) Stock Chart to make your own analysis
- WINDTREE THERAPEUTICS INC (WINT) Latest news and press-releases to stay up to date.
Does WINDTREE THERAPEUTICS INC (WINT) stock pay dividends?
WINT does not pay a dividend.
When does WINDTREE THERAPEUTICS INC (WINT) report earnings?
WINDTREE THERAPEUTICS INC (WINT) will report earnings on 2025-08-18, after the market close.
What is the Price/Earnings (PE) ratio of WINDTREE THERAPEUTICS INC (WINT)?
WINDTREE THERAPEUTICS INC (WINT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-400).
What is the Short Interest ratio of WINDTREE THERAPEUTICS INC (WINT) stock?
The outstanding short interest for WINDTREE THERAPEUTICS INC (WINT) is 1.39% of its float. Check the ownership tab for more information on the WINT short interest.
WINT Technical Analysis
WINT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to WINT. Both the profitability and financial health of WINT have multiple concerns.
WINT Financial Highlights
Over the last trailing twelve months WINT reported a non-GAAP Earnings per Share(EPS) of -400. The EPS increased by 98.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.17% | ||
| ROE | -163.47% | ||
| Debt/Equity | 0.12 |
WINT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to WINT. The Buy consensus is the average rating of analysts ratings from 6 analysts.